Ischemic stroke is a main complication of atrial fibrillation (cardiac arrhythmia). The aim of our study was to estimate the effects of citicoline (CDP-choline) therapy on the levels of circulating neurospecific protein markers in serum of the patients with ischemic stroke and atrial fibrillation. Fiftyfour patients (mean age 76 years) treated with citicoline in a dose of 2.0 g daily intravenously for 12 to 14 days in addition to basic treatment formed the examined group. Thirty-two patients (mean age 68.5 years) obtained only standard therapy and formed the control group. Serum levels of neuronal and glial protein markers, including glial fibrillary acidic protein (GFAP), a neurofilament light subunit (NF-L), myelin basic protein (MBP), and ionized calcium-binding adaptor molecule 1 (Iba1), were measured in patients of both groups before and after treatment; an immunoblotting technique followed by densitometry analysis were used. Supplementary citicoline treatment provided significant reductions of the levels of GFAP (33%, P = 0.034), NF-L (27%, P = 0.019), and MBP (32%, P = 0.018), as compared to the initial values, while there were no marked changes in the studied parameters in the control group. The results obtained allow us to hypothesize that therapeutic benefit of citicoline in patients with ischemic stroke and atrial fibrillation can be mediated through increasing neuronal viability, protecting against axonal injury, decreasing the level of reactive astrogliosis, preventing deficiencies in the blood-brain integrity, and reducing the intensity of demyelination. However, citicoline administration exerted no effect on the blood content of microglial marker Iba-1, thus possibly preserving an important functional significance of microglia, which is needed to resolve local inflammation and clear cellular debris, and also provide protective factors to reduce cell injury in the ischemic brain. The obtained results indicate that serum levels of neurospecific biomarkers are significant and clinically relevant indices of the efficiency of treatment of the above-mentioned pathologies and can be used for further investigations of the stroke pathophysiology and molecular mechanisms of nootropic-mediated neuroprotection.
Article PDF
Similar content being viewed by others
References
J. Kornej, C. S. Börschel, E. J. Benjamin, and R. B. Schnabel, “Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights,” Circ. Res., 127, No. 1, 4–20 (2020); doi:https://doi.org/10.1161/CIRCRESAHA.120.316340.
А. M. Alshehri, “Stroke in atrial fibrillation: review of risk stratification and preventive therapy,” J. Family Community Med., 26, No. 2, 92–97 (2019); doi:https://doi.org/10.4103/jfcm.JFCM_99_18.
D. A. Dulli, H. Stanko, and R. L. Levine, “Atrial fibrillation is associated with severe acute ischemic stroke,” Neuroepidemiology, 22, No. 2, 118–123 (2003); doi: https://doi.org/10.1159/000068743.
E. S. Donkor, “Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life,” Stroke Res. Treat., 2018, 3238165, (2018); doi:https://doi.org/10.1155/2018/3238165.
R. L. Jayaraj, S. Azimullah, R. Beiram, et al., “Neuroinflammation: friend and foe for ischemic stroke,” J. Neuroinflammation, 16, No. 1, 142 (2019); doi: https://doi.org/10.1186/s12974-019-1516-2.
Н. Stefansdottir, D. O. Arnar, T. Aspelund, et al., “Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts,” Stroke, 44, No. 4, 1020–1025 (2013); doi:https://doi.org/10.1161/STROKEAHA.12.679381.
A. Saglietto, M. Matta, F. Gaita, et al., “Stroke-indepen-dent contribution of atrial fibrillation to dementia, a meta-analysis,” Open Heart, 6, No. 1, e000984 (2019); doi: https://doi.org/10.1136/openhrt-2018-000984.
М. Gardarsdottir, S. Sigurdsson, T. Aspelund, et al., “Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion,” Europace, 20, No. 8, 1252–1258 (2018); doi:https://doi.org/10.1093/europace/eux220.
R. N. Kalaria, “Risk factors and neurodegenerative mechanisms in stroke related dementia,” Panminerva Med., 54, No. 3, 139–148 (2012).
T. A. Manolis, A. A. Manolis, E. J. Apostolopoulos, et al., “Atrial fibrillation and cognitive impairment: an associated burden or burden by association?,” Angiology, 71, No. 6, 498–519 (2020); doi:https://doi.org/10.1177/0003319720910669.
R. M. Ferreira Lisboa Da Silva, C. Madeira Miranda, T. Liu, et al., “Atrial fibrillation and risk of dementia: epidemiology, mechanisms, and effect of anticoagulation,” Front. Neurosci., 13, Article 18, 1–7 (2019); doi:https://doi.org/10.3389/fnins.2019.00018.
P. Jasielski, F. Piędel, M. Piwek, et al., “Application of citicoline in neurological disorders: a systematic re- view,” Nutrients, 12, No. 10, 3113 (2020); doi: https://doi.org/10.3390/nu12103113.
L. F. Borkenhagen and E. P. Kennedy, “The enzymatic synthesis of cytidine diphosphate choline,” J. Biol. Chem., 227, No. 2, 951–962 (1957).
J. J. Secades, J. Alvarez-Sabín, J. Castillo, et al., “Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials,” J. Stroke Cerebrovasc Dis., 25, No. 8, 1984–1996 (2016); doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010.
O. Y. Glushakova, A. V. Glushakov, E. R. Miller, et al., “Biomarkers for acute diagnosis and management of stroke in neurointensive care units,” Brain Circ., 2, No. 1, 28–47 (2016); doi:https://doi.org/10.4103/2394-8108.178546.
G. C. Jickling and F. R. Sharp, “Blood biomarkers of ischemic stroke,” Neurotherapeutics, 8, No. 3, 349–360 (2011); doi: https://doi.org/10.1007/s13311-011-0050-4.
М. Khalil, С. Е. Teunissen, М. Otto, et al., “Neurofilaments as biomarkers in neurological disorders,” Nat. Rev. Neurol., 14, No. 10, 577–589 (2018); doi: https://doi.org/10.1038/s41582-018-0058-z.
Y. Lee, B. H. Lee, W. Yip, et al., “Neurofilament proteins as prognostic biomarkers in neurological disorders,” Curr. Pharm. Des., 25, No. 43, 4560–4569 (2020); doi: https://doi.org/10.2174/1381612825666191210154535.
Z. Yang and K. K. Wang, “Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker,” Trends Neurosci., 38, No. 6, 364–374 (2015); doi:https://doi.org/10.1016/j.tins.2015.04.003
Y. Wang, G. Liu, D. Hong, et al., “White matter injury in ischemic stroke,” Prog. Neurobiol., 141, 45–60 (2016); doi:https://doi.org/10.1016/j.pneurobio.2016.04.005.
N. Wąsik, B. Sokół, M. Hołysz, et al., “Serum myelin basic protein as a marker of brain injury in aneurysmal subarachnoid haemorrhage,” Acta Neurochir. (Wien), 162, No. 3, 545–552 (2020); doi: https://doi.org/10.1007/s00701-019-04185-9.
J. Lee, G. Hamanaka, E. H. Lo, et al., “Heterogeneity of microglia and their differential roles in white matter pathology,” CNS Neurosci. Ther., 25, No. 12, 1290–1298 (2019); doi:https://doi.org/10.1111/cns.13266.
S. Xu, J. Lu, A. Shao, et al., “Glial cells: role of the immune response in ischemic stroke,” Front. Immunol., 11, 294 (2020); doi:https://doi.org/10.3389/fimmu.2020.00294.
Y. Sasaki, K. Ohsawa, H. Kanazawa, et al., “Iba1 is an actin-cross-linking protein in macrophages/microglia,” Biochem. Biophys. Res. Commun., 286, No. 2, 292–297 (2001); doi:https://doi.org/10.1006/bbrc.2001.5388.
A. D. Lafrenaye, S. Mondello, K. K. Wang, et al., “Circulating GFAP and Iba-1 levels are associated with pathophysiological sequelae in the thalamus in a pig model of mild TBI,” Sci. Rep., 10, No. 1, 13369 (2020); doi:https://doi.org/10.1038/s41598-020-70266-w.
“Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS),” Eur. Heart J., 42, No. 5, 507 (2020); doi: https://doi.org/10.1093/eurheartj/ehaa798.
G. Montalescot, U. Sechtem, S. Achenbach, et al., “2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology,” Eur. Heart J., 34, No. 38, 2949–3003 (2013). doi: https://doi.org/10.1093/eurheartj/eht296.
W. J. Powers, A. A. Rabinstein, T. Ackerson, et al., “Gui-delines for the early management of patients with acute ischemic stroke: 2019 Update to the 2018 Guidelines for the early management of acute ischemic stroke: A Guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, 50, No. 12, e344–e418 (2019); doi.org/10.1161/STR.0000000000000211.
C. M. Stoscheck, “Quantitation of protein,” Methods Enzymol., 182, 50–68 (1990); doi: https://doi.org/10.1016/0076-6879(90)82008-p.
X. Yi, J. Lin, Z. Han, et al., “Preceding antithrombotic treatment is associated with acute ischemic stroke severity and functional outcome at 90 days among patients with atrial fibrillation,” J. Stroke. Cerebrovasc. Dis., 28, No. 7, 2003–2010 (2019); doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.028.
Y. D. Cheng, L. Al-Khoury, and J. A. Zivin, “Neuroprotection for ischemic stroke: two decades of success and failure,” NeuroRx., 1, No. 1, 36–45 (2004); doi:https://doi.org/10.1602/neurorx.1.1.36.
M. Y. Martynov and E. I. Gusev, “Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke,” J. Exp. Pharmacol., 7, 17–28 (2015); doi:https://doi.org/10.2147/JEP.S63544.
J. J. Secades, “Citicoline: pharmacological and clinical review, 2016 update,” Rev. Neurol., 63, No. S03, S1–S73 (2016).
W. M. Clark, “Efficacy of citicoline as an acute stroke treatment,” Expert Opin. Pharmacother., 10, No. 5, 839–846 (2009); doi:https://doi.org/10.1517/17460440902835475.
K. Overgaard, “The effects of citicoline on acute ischemic stroke: a review,” J. Stroke. Cerebrovasc. Dis., 23, No. 7, 1764–1769 (2014); doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.01.020.
J. Alvarez-Sabín and G. C. Román, “Citicoline in vascular cognitive impairment and vascular dementia after stroke,” Stroke, 42, No. 1, 40–43 (2011); doi:https://doi.org/10.1161/STROKEAHA.110.606509.
P. Deb, S. Sharma and K. M Hassan, “Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis,” Pathophysiology, 17, No. 3, 197–218 (2010); doi:https://doi.org/10.1016/j.pathophys.2009.12.001.
A. A. Tykhomyrov, Y. S. Kushnir, V. S. Nedzvetsky, et al., “Citicoline affects serum angiostatin and neurospecific protein levels in patients with atrial fibrillation and ischemic stroke,” Ukr. Biochem. J., 91, No. 5, 34–45 (2019); doi: https://doi.org/10.15407/ubj91.05.034.
T. Matsunaga, D. W. Weihrauch, M. C. Moniz, et al., “Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide,” Circulation, 105, No. 18, 2185–2191 (2002); doi:https://doi.org/10.1161/01.cir.0000015856.84385.e9.
J. Krupinski, M. Abudawood, S. Matou-Nasri, et al., “Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1,” Vasc. Cell, 4, No. 1, 20 (2012); doi: https://doi.org/10.1186/2045-824X-4-20.
H. H. Nielsen, S. B. Soares, S. S. Høgedal, et al., “Acute neurofilament light chain plasma levels correlate with stroke severity and clinical outcome in ischemic stroke patients,” Front. Neurol., 11, 448 (2020); doi:https://doi.org/10.3389/fneur.2020.00448.
S. Köhler, U. Winkler, and J. Hirrlinger, “Heterogeneity of astrocytes in grey and white matter,” Neurochem. Res., 46, No. 1, 3–14 (2021); doi: https://doi.org/10.1007/s11064-019-02926-x.
A. Yuan, M. V. Rao, Veeranna, and R. A. Nixon, “Neurofilaments and neurofilament proteins in health and disease,” Cold Spring Harb. Perspect. Biol., 9, No. 4, a018309 (2017); doi:https://doi.org/10.1101/cshperspect.a018309.
S. Tiedt, M. Duering, C. Barro, et al., “Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke,” Neurology, 91, No. 14, e1338–e1347 (2018); doi:https://doi.org/10.1212/WNL.0000000000006282.
J. Cooper, S. Stukas, P. L. Hoiland, et al., “Quantification of neurological blood-based biomarkers in critically ill patients with coronavirus disease 2019,” Crit. Care. Explor., 2, No. 10, e0238 (2020); doi:https://doi.org/10.1097/CCE.0000000000000238.
Y. Zang, A. Liu, and L. Qi “The cytological mechanism and effects of hypertensive cerebral hemorrhage treatment by citicoline on serum GFAP and copeptin level,” Eur. J. Inflam., 17, 1–8 (2019); https://doi.org/https://doi.org/10.1177/2058739219867244.
M. Y. Khodanovich, A. A. Kisel, A. E. Akulov, et al., “Quantitative assessment of demyelination in ischemic stroke in vivo using macromolecular proton fraction mapping,” J. Cereb. Blood Flow. Metab., 38, No. 5, 919–931 (2018); doi:https://doi.org/10.1177/0271678X18755203.
H. Sh, X. Hu, R. K. Leak, et al., “Demyelination as a rational therapeutic target for ischemic or traumatic brain injury,” Exp. Neurol., 272, 17–25 (2015); doi: 10.1016/j.expneurol.2015.03.017.
T. Skripuletz, R. A. Linker, and M. Stangel, “The choline pathway as a strategy to promote central nervous system (CNS) remyelination,” Neural. Regen. Res., 10, No. 9, 1369–1370 (2015); doi:https://doi.org/10.4103/1673-5374.165498.
P. Grieb, “Beneficial effects of exogenous CDP-choline (citicoline) in EAE,” Brain, 138, No. 11, e388 (2015); doi: https://doi.org/10.1093/brain/awv140.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuryata, O.V., Kushnir, Y.S., Nedzvetsky, V.S. et al. Serum Levels of the Biomarkers Associated with Astrocytosis, Neurodegeneration, and Demyelination: Neurological Benefits of Citicoline Treatment of Patients with Ischemic Stroke and Atrial Fibrillation. Neurophysiology 53, 2–12 (2021). https://doi.org/10.1007/s11062-021-09907-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11062-021-09907-3